Pediatric Drugs and Vaccines - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. The market for 'Pediatric Vaccines' in this report is analyzed by the following Type: Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 120 companies including many key and niche players.

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Pediatrics: A Highly Underserved and Undervalued Group
Table 1: Global Birth Rate Statistics (2012) by Crude Birth Rates per 1000 Population for Key Countries
Pediatric Drugs Market - An Abode of Opportunities
Recent Pediatric Drug Approvals: 2011-2014
Pediatric Exclusivity Drives Manufacturers' Interest
The United States and Europe: Major Markets for Pediatric Drugs
Developing Markets to Witness Faster Growth
Table 2: Per-Capita Healthcare Expenditure in Select Regions (2013) (includes corresponding Graph/Chart)
Table 3: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP (2012) (includes corresponding Graph/Chart)
Table 4: Developing Regions Lead Children Population Globally (includes corresponding Graph/Chart)
Table 5: Asia-Pacific Proportion of Children (0-15 Years Age Group) by Select Country: 2013 (includes corresponding Graph/Chart)
Table 6: Latin American Proportion of Children (0-15 Years Age Group) by Country: 2013 (includes corresponding Graph/Chart)
Table 7: European Proportion of Children (0-15 Years Age Group) by Select Country: 2013 (includes corresponding Graph/Chart)
Table 8: The Middle Eastern Proportion of Children (0 Years Age Group) by Country: 2013 (includes corresponding Graph/Chart)
Anti-Infectives, and Anti-Allergy/Respiratory Drugs: Largest Selling Drug Classes
Pediatric Vaccines: The Fastest Growing Market Segment
Table 9: Global Prevnar 13 Vaccine Sales by Region: 2013 (includes corresponding Graph/Chart)
Prescription Hormone Drugs to Drive Pediatric Drugs Growth
Table 10: Global Pediatric Drugs Market by Therapeutic Class: Segments Ranked by Growth (includes corresponding Graph/Chart)
Clinical Studies and Pipeline Analysis
Table 11: Global On-Going Pediatric Drugs Clinical Studies by Country/Region (includes corresponding Graph/Chart)
Table 12: Global Pediatric Drugs Pipeline by Select Therapeutic Area (2012): Number of Drugs Under Development for Cancer, Genetic Diseases, Infectious Diseases, Neurological Diseases, Respiratory Diseases, Skin Disorders, Psychiatric Diseases, Cardiovascular Ailments, Diabetes, GI Diseases, Eye Diseases, Arthritis/Musculoskeletal, and Others (includes corresponding Graph/Chart)

2. MARKET TRENDS AND ISSUES
Potential for Pediatric Drugs Against Obesity-related Conditions
Table 13: Top 10 Countries with the Highest Proportion of Overweight Children (includes corresponding Graph/Chart)
Recent Phase III Completed Pediatric Cardiovascular Drugs
Lack of Adequate Funding Hinders Pediatric Drug Trials
Modeling & Simulation - A Powerful Tool for Pediatric Clinical Study Sponsors
Pharmacometrics Approaches Gain Traction Among US and EU Researchers
Challenges Associated with Adoption of Pharmacometric Approach
Guidelines for Conducting Ethically Correct Clinical Trials
Controversial Off-Label Drug Usage in the Pediatric Healthcare Market
The US Leads the Pediatric ADHD Drugs Market
Non-Stimulant ADHD Drugs Gaining Market
Table 14: Global ADHD Non-Stimulant Drugs Market by Type (2014): Percentage Market Share Breakdown of Prescription Sales for Kapvay, Intuniv, & Strattera (includes corresponding Graph/Chart)
Orphan Drugs for Pediatric Use Gain Popularity
Pediatric Orphan Drugs in Pipeline as of Year 2013
Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections
Select Pediatric Antiretroviral Drugs in Pipeline (2014)
Pediatric Growth Hormone Drug Market Offers Potential
Efforts to Ease Drug Use in Children Continues

3. REGULATORY ENVIRONMENT
Historical Lack of Focus on Pediatric Drug Development
Pediatric Guidelines by Different Regulatory Bodies
US Food and Drug Administration (USFDA)
Evolution of Regulations for Pediatric Drug Testing
New Regulations Incentivize Clinical Trials with Pediatric Subjects
PREA and BPCA - A Boon for Pharma Companies
European Medicines Agency (EMA)
EMA Rolls out Regulations for Pediatric Clinical Studies
Malaysian Pediatric Association (MPA)
Harmonization of Disparate Regional Regulations & Processes
the Next Step
International Conference on Harmonisation (ICH) Guidelines for Pediatric Formulations

4. PEDIATRIC VACCINES MARKET
Table 15: Number of Reported Cases for Vaccine-Preventable Diseases Globally: 2009-2013
Immunization Coverage
Table 16: Routine Immunization Coverage (2013): Percentage of Live Births/New Borns/Infants/ Children Vaccinated by Select Region
Table 17: Routine Immunization Coverage (2012): Percentage of Live Births/New Borns/Infants/ Children Vaccinated by Select Region
Table 18: Routine Immunization Coverage (2011): Percentage of Live Births/New Borns/Infants/ Children Vaccinated by Select Region
Market Share of Leading Pediatric Vaccine Manufacturers
Table 19: Global Pediatric Vaccines Market by Leading Players (2013): Percentage Market Share Breakdown of Dollar Sales for GlaxoSmithKline, Novartis, Sanofi-Pasteur, Merck, and Others (includes corresponding Graph/Chart)
Pediatric Vaccines in Pipeline
Pediatric Vaccine Types
Hemophilus Influenza Type B Vaccine
Available Hib and Combination Vaccines
Diphtheria/Tetanus/Pertussis Vaccines (DTaP Vaccines)
Available DTaP and Combination Vaccines
Table 20: Global DTP3 Immunization Coverage: 2003 (includes corresponding Graph/Chart)
Table 21: Developing Countries With % of Districts Achieving at Least 80% DTP3 coverage, 2013 (includes corresponding Graph/Chart)
Hepatitis A Vaccine
Available Hepatitis A and Combination Vaccines
Hepatitis B Vaccine
Hepatitis B Epidemiology
Available Hepatitis B and Combination Vaccines
Measles/Mumps/Rubella (MMR) Vaccines
Available MMR and Combination Vaccines
Rotavirus Vaccines
Available Rotavirus Vaccine
Polio Vaccines
Available Polio and Combination Vaccines
Varicella Vaccine
Available Varicella Vaccines
Pneumococcal Disease Vaccines
PCV 13 Replaces PCV 7
Available Pneumococcal Conjugate Vaccine
Meningococcal Vaccines
Available Meningococcal Polysaccharide and Combination vaccine
Combination Vaccines
Select Market Trends and Issues
Innovations Drive the Infectious Disease Market
Hepatitis B Combination Vaccines to Propel Market Growth
Table 22: Number of Countries Having Introduced HepB Vaccine: 2003-2013 (includes corresponding Graph/Chart)
Table 23: Global Infant HepB3 Coverage: 2003-2013 (includes corresponding Graph/Chart)
Conjugated and Protein-based Vaccines to Take over Polysaccharide Vaccines for Infectious Diseases
List of Infectious Disease Vaccines in the R&D Pipeline (2014)
Rising Women Workforce Propels Pediatric Vaccines Growth
Table 24: Female Employment-to-Population Ratio (%): 2002, 2007 & 2012 (includes corresponding Graph/Chart)

5. PEDIATRIC DISEASES - OVERVIEW, STATISTICS & TREATMENT
Infective Diseases
Recent Phase III Completed Pediatric Drugs for Infectious Diseases
Influenza
Treatment
Urinary Tract Infection (UTI)
Prevalence
Treatment
Mumps
Complications Related to Mumps
Prevention of Mumps in children
Incidence
Candidiasis
Fifth Disease
Molluscum Contagiosum
Roseola
Tetanus
Whooping Cough
Allergy and Respiratory Diseases
Recent Phase III Completed Pediatric Drugs for Respiratory Disorders
Prevalence Statistics
The US
Other Countries
Diphtheria
Incidence and Mortality Statistics
Upper Respiratory Infection (Common Cold)
Diagnosis & Treatment
Measles
Statistics
Asthma
Prevalence
Central Nervous System Disorders
Recent Phase III Completed Pediatric Drugs for Neurological/ Psychiatric Disorders
Mental Disorders
Prevalence
Attention Deficit Hyperactivity Disorder
Pain Control Medicines for Children
Statistics
Pain Statistics Among the American Children, General Population, and Other Adults
Malaria
Anemia
Treatment for Anemia in Children
Recent Phase III Completed Pediatric Drugs for Genetic Disorders

6. LIST OF SELECT FDA APPROVED PEDIATRIC DRUGS

7. PRODUCT INTRODUCTIONS/INNOVATIONS
Sanofi Pasteur Receives prequalification status for Shan5™
Immune Response Receives US FDA Orphan Drug Status for Remune Vaccine
Merck’s ISEMTRESS Receives FDA Approval
Valneva Receives FDA Market Exclusivity for IXIARO®
Merck Receives FDA Grant for Production of Live Virus Material
Flu Vaccine Receives FDA Approval
Sanofi Pasteur Receives EU Approval for Hexyon/Hexacima Pediatric Vaccine
Novartis Receives FDA Approval for Menveo
ROTAVAC Receives Approval
MenHibrix Receives Approval
GSK Receives EU Approval for Nimenrix
Sanofi Pasteur to Launch New Vaccines
FDA Approves Omalizumab as Safe Drug for Children
ACETO Corporation to unveil generic Cleocin Pediatric Antibiotic
GlaxoSmithKline Receives Approval for MenHibrix
CHMP Grants Approval for Glaxo’s Nimenrix
Sanofi Receives EMA Approval for Hexaxim

8. RECENT INDUSTRY ACTIVITY
GSK Forms Joint Venture with Biological E to Develop Pediatric Vaccine
Novartis Discontinues JV with Panaceia Biotec
GSK Inks a Joint Venture with Biological E
Nuron Biotech Inks Licensing agreement with Mitsubishi Tanabe
DNDi Collaborates with Cipla For Development of 4-in-1 Pediatric Drug
Merz Acquires CUVPOSA Oral Solution

9. FOCUS ON SELECT GLOBAL PLAYERS
Actelion Pharmaceuticals Ltd (Switzerland)
Abbott Laboratories (US)
Allergan, Inc. (US)
Amgen, Inc. (US)
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (US)
Crucell N.V. (The Netherlands)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (US)
GlaxoSmithKline plc. (UK)
InfaCare, Inc. (USA)
Merck & Co., Inc. (US)
Merck Serono (Switzerland)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (US)
Sanofi S.A (formerly Sanofi-Aventis) (France)
Shionogi Inc. (US)
Shire Pharmaceuticals Group Plc (UK)

10. GLOBAL MARKET PERSPECTIVE
Table 25: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic
Table 45: World 15-Year Perspective for Other Pediatric Drugs by Geographic Region - Percentage Share
Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$
Table 44: World Historic Review for Other Pediatric Drugs by Geographic Region - US, Canada, Japan, Europe, Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with
Table 43: World Recent Past, Current & Future Analysis for Other Pediatric Drugs by Geographic Region - US, Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 42: World 15-Year Perspective for Pediatric CNS Drugs by Geographic Region - Percentage Share Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$
Table 41: World Historic Review for Pediatric CNS Drugs by Geographic Region - US, Canada, Japan, Europe, Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 40: World Recent Past, Current & Future Analysis for Pediatric CNS Drugs by Geographic Region - US, Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 39: World 15-Year Perspective for Pediatric Anti-infective Drugs by Geographic Region - Percentage Share Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$
Table 38: World Historic Review for Pediatric Anti-infective Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 37: World Recent Past, Current & Future Analysis for Pediatric Anti-infective Drugs by Geographic Region - US, Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 36: World 15-Year Perspective for Pediatric Anti-infective Drugs by Geographic Region - Percentage Share Billion for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 35: World Historic Review for Pediatric Anti-infective Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 34: World Recent Past, Current & Future Analysis for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 33: World 15-Year Perspective for Pediatric Allergy & Respiratory Drugs by Geographic Region - Percentage Share Billion for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 32: World Historic Review for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 31: World Recent Past, Current & Future Analysis for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 30: World 15-Year Perspective for Pediatric Allergy & Respiratory Drugs by Geographic Region - Percentage Share Billion for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 29: World Historic Review for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 28: World Recent Past, Current & Future Analysis for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 27: World 15-Year Perspective for Pediatric Allergy & Respiratory Drugs by Geographic Region - Percentage Share
Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 26: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$
Table 25: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 24: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Shareasia,
Table 23: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 22: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 21: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share
Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 18: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share
Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 15: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share
Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 13: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 12: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share
Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 46: World Recent Past, Current & Future Analysis for Pediatric Vaccines by Type - Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 47: World 15-Year Perspective for Pediatric Vaccines by Type - Percentage Share Breakdown of Dollar Sales for Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Other Markets for Years 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A. Market Analysis
Major Diseases Afflicting Children in the US
Pediatric Drugs Market in the US
Market Trends and Issues
Pediatric Drugs Witness Supply Shortages
Measures Taken to Reduce Supply Shortages
Low Enthusiasm for Drug Development Research
Lack of New Drugs in Pipeline
Manufacturing Challenges
New Pediatric Indications for Existing Drugs
Pediatric ADHD Drugs Continue to Witness High Prescription Rate
Table 48: The US ADHD Market by Segment (2013): Percentage Share of Total Prescriptions for Adult ADHD and Pediatric ADHD (includes corresponding Graph/Chart)
Rising Incidence of Diabetes Mellitus in North America
Table 49: North America Incidence of Type 1 Diabetes in Children (2012) (includes corresponding Graph/Chart)
FDA Approved Antidepressants in Pediatric Patients
FDA-Approved Antidepressant Medication by Indication and Age-Group
Use of Antidepressant Medications in Pediatric Patients: Treatment Guidelines
Pediatric Antidepressant Drugs and Black Box Warnings
List of Drugs Mandated by FDA to Carry Black Box Warning on Suicidal Ideation in Adolescents and Children
OTC Drugs Market to Maintain Growth Momentum
Regulatory Environment
Evolution of Regulations for Pediatric Drug Testing
New Regulations Incentivize Clinical Trials with Pediatric Subjects
PREA and BPCA - A Boon for Pharma Companies
Pediatric Vaccines Market Witnesses Rapid Growth
Anti-Vaccination Trend Restricting the Market
Improved Pricing Scenario for Pediatric Vaccines
Affordable Care Act Favoring the US Pediatric Drugs Market
Child Population & Birth Rates
Table 50: Child Birth in the US: Breakdown of Number of Births per 1,000 Population for the Years 2003 through 2012 (includes corresponding Graph/Chart)
Opportunity Indicator
Table 51: Number of reported cases for Vaccine-Preventable Diseases in American Regions
Table 52: Routine Immunization Coverage in the US (2011-2013): Percentage of Live Births/ New Borns/Infants/Children Vaccinated
Immunization Program
Recommended Immunization Schedule for Persons Aged 0 through 18 Years - United States, 2014
Catch-Up Immunization Schedule for Persons Aged 4 Months through 18 Years Who Start Late or Who are More than 1 Month Behind —United States, 2014
Product Launches/Approvals
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics
Table 53: The US Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class
Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 54: The US Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines,
Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 55: The US 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

2. CANADA
A. Market Analysis
Opportunity Indicator
Table 56: Canadian Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated
B. Market Analytics
Table 57: Canadian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class
Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 58: Canadian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 59: Canadian 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

3. JAPAN
A. Market Analysis
Opportunity Indicator
Table 60: Japanese Routine Immunization Coverage (2011-2013): Percentage of Live Births/ New Borns/Infants/Children Vaccinated
B. Market Analytics
Table 61: Japanese Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class
Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 62: Japanese Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 63: Japanese 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4. EUROPE
A. Market Analysis
Table 64: Proportion of Children in the 0-15 Years Age Group by Country in Europe (2013) (includes corresponding Graph/Chart)
EMA Rolls out Regulations for Pediatric Clinical Studies
Market Challenges
Cost Considerations
Child-Friendly Drug Forms
Product Approval
B. Market Analytics
Table 65: European Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region
France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 66: European Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France,
Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 67: European 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

Table 68: European Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class

Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 69: European Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 70: European 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

A. Market Analysis
Opportunity Indicator

Table 71: French Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated

Product Launches
Focus on Select Major Player

B. Market Analytics

Table 72: French Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class

Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 73: French Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 74: French 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4b. GERMANY

A. Market Analysis
Opportunity Indicator

Table 75: German Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated

Select Major Player

B. Market Analytics

Table 76: German Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class

Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 77: German Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 78: German 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4c. ITALY

A. Market Analysis
Opportunity Indicator

Table 79: Italian Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated
Borns/Infants/Children Vaccinated

B. Market Analytics

Table 80: Italian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class

Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 81: Italian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 82: Italian 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

A. Market Analysis

Opportunity Indicator

Table 83: The UK Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated

Focus on Select Major Players

B. Market Analytics

Table 84: The UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class

Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 85: The UK Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 86: The UK 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4e. SPAIN

A. Market Analysis

Opportunity Indicator

Table 87: Spanish Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated

B. Market Analytics

Table 88: Spanish Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class

Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 89: Spanish Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

Table 90: Spanish 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

A. Market Analysis

Opportunity Indicator

Table 91: Russian Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated

B. Market Analytics

Table 92: Russian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class

Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and
Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 93: Russian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 94: Russian 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE
A. Market Analysis
Opportunity Indicator
Table 95: Number of reported cases for Vaccine-Preventable Diseases in Eastern European Region
Focus on Select Major Players
B. Market Analytics
Table 96: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 97: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 98: Rest of Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A. Market Analysis
Table 99: Proportion of Children in the 0-15 Years Age Group by Country in Asia-Pacific (2013) (includes corresponding Graph/Chart)
Burgeoning Middle Class Population in Asia Bodes Well for Market Growth
Table 100: World Middle Class Population (2012 & 2030): Percentage Share Breakdown by Region - North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (includes corresponding Graph/Chart)
Vaccines Market in Asia-Pacific
Opportunity Indicator
Table 101: Number of reported Cases for Vaccine-Preventable Diseases in South-East Asia
Table 102: Number of reported cases for Vaccine-Preventable Diseases in West-Pacific Region
B. Market Analytics
Table 103: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 104: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 105: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 106: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 107: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 108: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5a. CHINA
A. Market Analysis
Chinese Market Outlook
Opportunity Indicator
Growing Pediatric Market in China
Table 110: Chinese Population (2001-2013): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart)
China Sets Eyes on Supporting Pediatric Drugs Market
Expediting R&D and Drug Review Process
Strengthening Policies Related to Pediatric Drug Production and Supply
Enhancing Clinical Usage of Pediatric Drugs
Implementation of Safety and Quality Control Measures
Harmonizing Chinese and Western Drugs
Increasing Public Awareness

B. Market Analytics
Table 111: Chinese Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class
Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 112: Chinese Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 113: Chinese 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5b. INDIA
A. Market Analysis
Opportunity Indicator
Table 114: Indian Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated
Pediatric Drug Development in India
Strategic Corporate Developments
Product Approval
B. Market Analytics
Table 115: Indian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class
Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 116: Indian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 117: Indian 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5b. REST OF ASIA-PACIFIC
A. Market Analysis
Opportunity Indicator
Table 118: Routine Immunization Coverage in Republic of Korea (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated
B. Market Analytics
Table 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 121: Rest of Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class
Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA
A. Market Analysis
Table 122: Proportion of Children in the 0-15 Years Age Group by Country in Latin America (2013) (includes corresponding Graph/Chart)
Opportunity Indicator
Table 123: Brazilian Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated
B. Market Analytics
Table 124: Latin American Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 125: Latin American Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 126: Latin American 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD
A. Market Analysis
Opportunity Indicator
Table 127: Proportion of Children in the 0-15 Years Age Group by Country in the Middle East (2013) (includes corresponding Graph/Chart)
Table 128: Saudi Arabian Population (2001-2013): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart)
Table 129: Number of Reported Cases for Vaccine-Preventable Diseases in Africa: 2009-2013
Table 130: South African Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated
Table 131: Central African Routine Immunization Coverage (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated
B. Market Analytics
Table 132: Rest of World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 133: Rest of World Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 134: Rest of World 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs Market for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

8. APPENDIX 1: LIST OF ALREADY APPROVED FDA DRUGS FOR WHICH LABELING CHANGES WERE MADE TO INCLUDE PEDIATRIC INDICATIONS
2014 & 2013
New Pediatric Labeling Information

9. APPENDIX 2: LIST OF DRUGS OBTAINING PEDIATRIC EXCLUSIVITY BY FDA
Pediatric Exclusivity Granted
August 2014
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 120 (including Divisions/Subsidiaries - 131)
The United States (78)
Canada (4)
Japan (5)
Europe (35)
- France (4)
- Germany (4)
- The United Kingdom (5)
- Rest of Europe (22)
Asia-Pacific (Excluding Japan) (8)
Latin America (1)

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Pediatric Drugs and Vaccines - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/1824138/
Office Code: SCH3ZAXT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 6930</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users:</td>
<td>USD 9405</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users:</td>
<td>USD 11880</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB89533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp